ImmunoPrecise Antibodies Ltd. - President and CEO, Jennifer Bath
President and CEO, Jennifer Bath
Source: U-Protein Express
  • ImmunoPrecise Antibodies (TSXV:IPA) has received a Bioscience Innovation Grant from the US state of North Dakota, valued at approximately C$106,000
  • The grant will help the company develop a treatment platform for COVID-19 and related pathogens
  • The company is actively seeking further grant funding to progress the project
  • In related news, the company has loaned $294,000 through the US government COVID relief act to secure payroll payments during the pandemic
  • ImmunoPrecise Antibodies (IPA) is up 2.56 per cent, with shares trading for $0.80 and a market cap of $54.4 million 

ImmunoPrecise Antibodies (TSXV:IPA) has received a Bioscience Innovation Grant from the US state of North Dakota.

The grant is valued at approximately C$106,000 and is intended to help the company develop a treatment platform. The platform would allow rapid development of treatments for COVID-19 and other related diseases.

North Dakota’s Agriculture Commissioner stated the grant will help the state remain on the cutting-edge of bioscience innovation.

The company is now seeking further grants from other sources to continue developing the platform.

Jennifer Bath, President and CEO of ImmunoPrecise, believes funding like this will help move development forward.

“ImmunoPrecise is in the process of applying for both state and federal grants to support the development of a treatment for COVID-19.

“We turned first to the State of North Dakota, given their strong history of support for Biotechnology and Innovation. It is with gratitude we accept the Bioscience Innovation Grant and we are confident we can leverage this funding, along with our research advances, to continue to build on our current successes,” she said.

In related news, the company has received a loan for approximately $294,000 from the US government. The loan ensures the company’s payroll is secure during the COVID-19 pandemic and is part of the government’s coronavirus relief act.

The company is also raising $2 million through a non-brokered private placement of debentures. The debentures have an interest rate of 10 per cent per year and can be converted to $0.85 a share.

ImmunoPrecise Antibodies (IPA) is up 2.56 per cent, with shares trading for $0.80 at 2:14pm EST. 

More From The Market Online

Clearmind Medicine to begin alcohol use disorder clinical trial

Clearmind Medicine (CSE:CMND) has received approval to begin its phase I/IIa clinical trial for alcohol use disorder in Israel.
WELL Health - Hamed Shahbazi, Founder and CEO (third from right).

WELL Health streamlining business towards profitable growth

WELL Health (TSX:WELL) has made an integration update to streamline its business operations and position itself for profitable growth.

An investor’s gateway into the cancer immunotherapy market is with this Canadian biotechnology company 

The overarching cancer immunotherapy market continues growing at unprecedented rates, and BioVaxys Technology is ready to capitalize on it.

Buzz on the Bullboards: Where volatility meets opportunity

Some indices hit lows not seen in nearly a year after a concerning inflation report, only to bounce back the next day.